{
    "SPADE_N_03597": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_03597",
            "Peptide Name": "H-0, Hymenochirin-1B",
            "Source": "Hymenochirus boettgeri (Congo dwarf clawed frog)",
            "Family": "Unknown",
            "Gene": "Not found",
            "Sequence": "IKLSPETKDNLKKVLKGAIKGAIAVAKMV",
            "Sequence Length": 29,
            "UniProt Entry": "No entry found",
            "Protein Existence": "Experimental evidence at transcript level",
            "Biological Activity": [
                "Antimicrobial",
                "Anticancer"
            ],
            "Target Organism": "[Ref.30789695] Cancer cell lines:A549 (IC50 = 15.22 ± 0.21 μM), HCT116 (IC50 = 12.76 ± 0.43 μM), HepG2 (IC50 = 8.07 ± 0.21 μM)",
            "Hemolytic Activity": "[Ref.30789695] It has 5%, 6.3%, 7.7%, 10%, 10.7%, 15.3%, 9%, 15% and 9.7% hemolysis against fresh rabbit blood cells at 0.010, 0.25, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0, 25.0μM",
            "Cytotoxicity": "No cytotoxicity information found in the reference(s) presented",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "No detailed structure description found.",
            "Formula": "C139H251N37O37S",
            "Mass": 3064.77,
            "PI": 10.13,
            "Net Charge": 5,
            "Hydrophobicity": 0.17,
            "Half Life": "Mammalian:20 hourYeast:30 minE.coli:>10 hour",
            "Function": "Antimicrobial, Anticancer, Immunomodulatory and Antidiabetic activity.",
            "Comments": "As a cationic, amphipathic, α-helical, 29-residue,host defense peptide,  Hymenochirin-1B is the predominant pharmacological active component of four hymenochirins, which showed a wide range of biological activities, such as antimicrobial, anticancer, immunomodulatory, and antidiabetic activities. Surprisingly, we don't find the entry introducing Hymenochirin-1B in UniProt (2021-3-29).",
            "Literature": [
                {
                    "Title": "Improving Selectivity, Proteolytic Stability, and Antitumor Activity of Hymenochirin-1B A Novel Glycosylated Staple Strategy",
                    "Pubmed ID": "30789695",
                    "Reference": "ACS Chem Biol. 2019 Mar 15;14(3)516-525. doi 10.1021/acschembio.9b00046. Epub 2019 Mar 1.",
                    "Author": "Yulei Li, Yihan Zhang, Minghao Wu, Qi Chang, Honggang Hu, Xia Zhao",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30789695"
                }
            ],
            "Frequent Amino Acids": "KAI",
            "Absent Amino Acids": "CFHOQRUWY",
            "Basic Residues": 7,
            "Acidic Residues": 2,
            "Hydrophobic Residues": 15,
            "Polar Residues": 17,
            "Positive Residues": 7,
            "Negative Residues": 2,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_23800",
                    "Similarity": 1.0,
                    "Sequence": "IKLSPTKDLKKVLKGAIKGAIAVAKMV"
                },
                {
                    "SPADE_ID": "SPADE_UN_23801",
                    "Similarity": 1.0,
                    "Sequence": "IKLSPETKDNLKKVLKGIKGIAVAKMV"
                },
                {
                    "SPADE_ID": "SPADE_UN_23802",
                    "Similarity": 1.0,
                    "Sequence": "IKLSPTKDLKKVLKGIKGIAVAKMV"
                }
            ]
        }
    }
}